G.L. Pharma
Austrian pharmaceutical company
From Wikipedia, the free encyclopedia
G.L. Pharma (also known as Gerot Lannach) is an Austrian pharmaceutical company headquartered in Lannach, Styria. The company manufactures pharmaceuticals for a wide range of therapeutic areas, including the treatment of allergies, bacterial infections, diabetes, cancer, chronic pain and Parkinson's disease.[2] It also produces Potassium iodide tablets used for iodine thyroid blocking in the event of a nuclear incident involving the release of radioactive 131I.[1]
| Company type | GmbH |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1947 |
| Headquarters | Lannach, Austria |
Key people | Ilse Bartenstein, Martin Bartenstein, Johann Danklmaier |
| Revenue | €195 million[1] (2020) |
Number of employees | approx. 910 |
| Website | gl-pharma.com |
In 2019, the company recorded the largest single order in its history when the German Federal Office for Radiation Protection ordered 190 million iodine tablets as a precautionary measure in case of a major nuclear emergency involving the release of 131I.[3][4]
G.L. Pharma traces its origins to the Lannacher Heilmittel GmbH, founded in 1947 in Lannach. The company was acquired in 1966 by Leopold and Hannelore Bartenstein. In 1997, the Vienna-based pharmaceutical manufacturer Gerot Pharmazeutika was purchased. Both companies were merged in 2009 to form G.L. Pharma under the brand name Gerot Lannach.[1]
In spring 2019, G.L. Pharma began expanding its production facilities in Lannach. The investment, intended to create space for 100 new jobs, was valued at €60 million.[5]
G.L. Pharma is headquartered in Lannach Castle and is a subsidiary of Bahopharm GmbH, which is owned by the Bartenstein family. Genericon Pharma is a sister company of G.L. Pharma GmbH under the Bahopharm group.[6]